Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 5/20 | 0.37 |
| ▸ | FLT3 | P36888 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDR | P35968 | 2/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.34 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.34 |
| ▸ | FCER2 | P06734 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.33 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.33 |
| ▸ | IGF1R | P08069 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7132935 | 0.81 | MEN1 (0.56) | RETFLT3MEN1KMT2AKDR | |
| SCHEMBL7133302 | 0.80 | MAPT (0.32) | MEN1KMT2A | |
| SCHEMBL7139244 | 0.79 | MEN1 (0.51) | RETFLT3MEN1KMT2AKDR | |
| SCHEMBL7138309 | 0.79 | MEN1 (0.51) | RETFLT3MEN1KMT2AKDR | |
| SCHEMBL7130446 | 0.78 | NTRK1 (0.63) | RETMEN1KMT2AKDRGSK3B | |
| SCHEMBL7131400 | 0.76 | MEN1 (0.42) | RETFLT3MEN1KMT2AKDR | |
| SCHEMBL7131343 | 0.76 | NPC1 (0.56) | RETFLT3MEN1KMT2AKDR | |
| SCHEMBL7134441 | 0.76 | MYC (0.43) | RETFLT3MEN1KMT2AKDR | |
| SCHEMBL5369354 | 0.75 | MAP3K7 (0.54) | RETFLT3MEN1KMT2AGSK3B | |
| SCHEMBL5376938 | 0.75 | ERBB2 (0.43) | RETMEN1KMT2AKDRPDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | FRK, PTK2, DSTYK | RET 283/4885FLT3 395/4885MEN1 3855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.